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ABSTRACT
A recent discussion expanded the debate about
the experimental research on Gelsemium in
anxiety. Herbal medicine is widely used in
anxiety and mood disorders, often with
contradictory evidence, although some
authors are yet prompted to promote their full
introduction in pharmacology as a promising
therapy. Complementary and alternative
medicine (CAM) in anxiety is particularly
appreciated by individual healthcare, but
deserves further investigation, as many critical
issues have been recently raised. Comments
about the ability of negligible doses of
Gelsemium hydroalcoholic extracts to affect
gene expression were recently reported.
Keywords: Gelsemium; Gelsemine; GABA
receptors; Behaviour; Anxiety
INTRODUCTION
Herbal medicine is widely used in anxiety and
mood disorders, often with contradictory
evidence [1], although some authors are yet
prompted to promote their full introduction in
pharmacology as a promising therapy [2, 3].
Complementary and alternative medicine
(CAM) in anxiety is particularly appreciated
by individual healthcare [4], but deserves
further investigation, as many critical issues
have been recently raised. [5, 6]. As a matter of
fact, a recent discussion expanded the debate
about the experimental research on Gelsemium
in anxiety [7–11]. This Commentary tries to
elucidate major issues causing this debate by
addressing the numerous aspects raised in
comments published elsewhere in the
literature.
The anxiolytic property of Gelsemium plant
has been extensively reviewed [11–14]. Raw
alcoholic extracts from Gelsemium sempervirens
showed the ability to modify the response of
mice in behavioural tests and reduce anxiety
[15]. In this research, the anxiolytic property
related to Gelsemium extracts has been quite
exclusively associated with the alkaloid
gelsemine [13, 15, 16]; yet, Gelsemium plants
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contain many further alkaloids with anxiolytic
potential [12], thus suggesting that the anti-
anxiety activity of Gelsemium sempervirens may
come indifferently from gelsemine, koumine, or
gelsevirine or a complex mixture of several
active alkaloids [13]. Actually, plants from the
genus Gelsemium are considered a source of
potential anxiolytic substances [12]. This means
that experimental neuroscience based on the
possible use of Gelsemium as a CAM therapy for
anxiety shows many difficulties in highlighting
a single active principle accounting for the
presumptive evidence of efficacy observed in
in vitro and animal models. The current debate
on Gelsemium and anxiety includes the many
issues exemplified in Table 1, where bias,
comments, and replies to comments are
thoroughly summarized. A comprehensive
neuropharmacology of Gelsemium should take
into consideration any aspect coming from
issues described within the reported table.
Most of articles dealing with Gelsemium in
anxiety pertain to CAM therapy. A Pubmed/
Medline search of the MESH term Gelsemium
allowed us to retrieve 121 papers from 1945 to
date, of which 83 dealt with Gelsemium in
herbal medicine and CAM. The excellent
journal Psychopharmacology published at least
two papers about Gelsemium in homeopathy
[15, 17], showing either a cataleptogenic or
anxiolytic action by Gelsemium 30cH, i.e. a
theoretical gelsemine concentration less than
6 9 10-60 mol/L [15]. In this circumstance, it
should be quite difficult to associate any
neurologic effect whatsoever with any active
molecule present in serially diluted extracts
from the Gelsemium plant. Moreover,
comments were raised about the presence of
ponderable, significant moles of ethanol added
as a co-solvent with water [9, 10, 18, 19]. While
a Gelsemium 30CH might have negligible traces
of possible active principles, its ethanol content
would be within the range 0.5–1.0 mM [18], an
occurrence that raised comments about the
active molecule in the observed and reported
effects [15, 18–21]. These issues prompted this
author to address the debate about Gelsemium in
the following step-points.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by the
author.
ACTIVE PRINCIPLES, SOLVENT,
AND MECHANISM OF ACTION
Alcoholic raw extracts from plants contain
alkaloids and other molecules that may
interfere with a plain interpretation of the
pharmacology of active principles, due to the
complex interaction, either synergistic or
competitive, existing between different
substances in the raw mixture [11].
Particularly, gelsemine has been recently
associated with a well-defined neuro-
pharmacological mechanism related with
anxiety. It modulates anxiety in laboratory
animals at a sub-micromolar dose range, and
in fact, gelsemine doses from 10-6 to 10-10 M
induce an anxiolytic action in rats in the
elevated plus-maze test [13]. Gelsemine is a
Gelsemium derived alkaloid sharing a chemical
and functional kinship with strychnine [22]. In
rat spinal cords, gelsemine showed an additive
effect with glycine in increasing the production
of the neurosteroid allopregnenolone (3a,5a-
tetraidroprogesterone or 3a-idrossi-5a-pregnan-
20-one, 3a,5a-THP), which in turn should
increase anxiety, due to an increased
hippocampal expression of a4bd GABAA
receptors [23, 24]. 3a,5a-THP is a positive
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Table 1 Fundamental issues in the research about Gelsemium and anxiety
Topic Issues and bias References (A) Comments
and (B) replies
in:
Active principles Gelsemine (3-ethenyl-1-methyl-2,3,3a,7,8,8a-hexahydro-
1 h,5 h-spiro[3,8,5-(ethane[1, 1, 2]triyl)oxepino[4,5-
b]pyrrole-4,30-indol]-20(10h)-one) was the only active





• BIAS 1. Gelsemium plant extracts contain other alkaloids
with anxiolytic activity (e.g. koumine, gelsevirine)
• BIAS 2. The anxiolytic activity of Gelsemium alcoholic
extracts was not further dissected in order to identify one or
more coworking active principles;
• BIAS 3. Gelsemine was supposed to be the only active
principle working in Gelsemium extracts on the simple basis of
previous in vitro pharmacological evidence
• BIAS 4. Adverse effects not evaluated
Solvent and test
samples
Gelsemium extracts were used as a 30 % EtOH/water mixture
and further diluted with EtOH and water to have test samples
[14–16,
20, 21]
A [8, 9, 18]
B [10, 19]
• BIAS 5. Refs [15, 16, 20, 21] started from a raw EtOH/H2O
Gelsemium extract containing 30 % alcohol (*50 mM
EtOH), then a 1:100 dilution into water with 30 % EtOH
and a 1.100 dilution into water (1:10,000) followed. Final
dilution contained *500 lM EtOH, still biologically active
• BIAS 6. Ethanol is effective on gene expression at molar




• BIAS 7. Behavioural tests were performed on mice and
in vitro conﬁrmatory cellular tests on humans
• BIAS 8. Behavioural tests performed did not include speciﬁc
tests on anxiety, depression, sedation
• BIAS 9. Operators treating animals performed behavioural
tests
[15, 16] A [8, 9]
B [10]
Experimental setting
(b): in vitro cell
model
In vitro cell model: human neuroblastoma cell line
• BIAS 10. Criticism in gene expression performing and
interpretation
[20, 21] A [18]
B [19]
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modulator of GABAA receptors and may cause
anxiogenic and adverse mood effects in
particular circumstances involving steroid
withdrawal [25]. The effect of 3a,5a-THP on
GABAA receptors is particularly complex in
neuroscience and depends on the many
factors related to chronic stress, the expression
level of the GABA receptor a4 subunit, the
direction of chloride-mediated ionic fluxes
created by these target receptors, leading also
to a downregulation or dampening in the
benzodiazepine ability to modulate this
mechanism [8, 25]. This should suggest that,
at least in animal models, the anxiolytic action
attributed to gelsemine may be actually caused
by other mechanisms, and more caution is
requested about a presumptive 3a,5a-THP/
GABA relationship with anxiolytic effects.
Interestingly, recent reports on the effect of
hydroalcoholic extracts from Gelsemium
sempervirens on mouse behaviour showed a
marked insensitivity of mice to diazepam [26].
In this circumstance, criticism was raised about
setting and evaluation of mice stress response in
behavioural tests [8, 9]. Furthermore, other
alkaloids contained in Gelsemium plants, such
as koumine, have been associated with a 3a,5a-
THP/GABA receptor signaling [26].
Yet, the anxiolytic activity exerted by
Gelsemium might be caused by many further
mechanisms. Many Gelsemium-derived
alkaloids, such as kuomine and gelsenicine
[26, 27] exert a nociceptive effect. Particularly,
gelsemine acts on chronic pain through the
Table 1 continued





Associated exclusively with gelsemine and considering the
allopregnenolone/GABAR pathway
• BIAS 11. The anxiolytic activity of Gelsemium may derive
from other alkaloids besides gelsemine
• BIAS 12. Gelsemine can be anxiolytic through a GlyR/
GlyT1-mediated mechanism
[15] A [8, 18]
B [19]
Dilutions and ponderal chemistry. Solvents
• BIAS 13. Pharmacological interpretation may be hindered by
diluted test solutions with negligible amounts of active
principles
• BIAS 14. Ethanol amount is much more higher than any
Gelsemium derived active principles in tested solutions besides
Gelsemium 2CH
Statistics Statistics with pooling data
• BIAS 15. Pooling data projected to retrieve positive
evaluation of the mechanism
• BIAS 16. Blinded confounders with the same operator in
treating and performing test with animals
[15] A [8]
B [10]
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activation of spinal a3 glycin receptors (GlyR)
[22]. This should suggest that the anxiolytic
activity associated with Gelsemium may not
directly come from GlyR activation, but most
probably from the contribution of activated
GlyR on the anziolytic activity of glycine
transporter inhibitors [28]. Therefore, it is very
difficult to highlight the neurological
mechanism by which Gelsemium exerts its
anxiolytic activity, when Gelsemium extract is
used within a micromolar-millimolar range.
Furthermore, Gelsemium contains a lot of
molecules with sedative, anti-depressant
activity [8], for which it is very difficult to
ascertain an anxiolytic activity only by widely
used, not properly suited behavioural tests [8, 9,
15]. In this perspective, other components
contained in Gelsemium-derived test solutions
such as ethanol, may be significantly involved
[8]. Describing a comprehensible overview of
the anxiolytic activity of Gelsemium extracts, is
hampered also by the recent observation that
flavonoids, which are present in the Gelsemium
plant, may exert an anxiolytic action [29].
Furthermore, the involvement of the
GABAergic system in anxiety models is yet
controversial, because anxiogenic/anxiolytic
activity on GABAergic systems may be
modulated by different types of orexins [30].
This strongly suggests that the interpretation of
Gelsemium anxiolytic activity by involving a
single, defined mechanism [15] may be
reductive.
A recent behavioural research on ICR-CD1
mice used an hydroalcoholic extract of
Gelsemium sempervirens, which was serially
diluted to reach negligible concentrations of
potentially bio-active molecules [15]. ICR-CD1
mice are not particularly suited for behavioural
tests compared to the more considered
C57BL6 J mouse [31]. A large number of the
laboratory mice sold and used by investigators
around the world are considered to
be outbred or random-bred. Popular stocks of
such mice in the US include CD-1 (Charles
River Breeding Laboratories), Swiss Webster
(Taconic Farms), and ICR, and NIH Swiss (both
from Harlan Sprague–Dawley). Outbred mice
are used for the same reasons as F1 hybrids—
they exhibit hybrid vigor with long life spans,
high disease resistance, early fertility, large and
frequent litters, low neonatal mortality, rapid
growth, and large size. However, unlike
F1 hybrids, outbred mice are genetically
undefined. Nevertheless, outbred mice are
bought and used in large numbers simply
because they are less expensive than any of
the genetically defined strains. These animals
are widely used for behavioural tests.
Behavioural tests most commonly used, such
as the light dark box test (LDBT) or open field
test (OFT), should evaluate time spent at light,
without hiding into a small pitch dark hole or
walking on the centre of an empty arena, as a
measure of stress lacking or anxiety absence for
tested animals [15], yet these tests are used also
to evaluate sedation, fear-related stress and
depression [9] and are much less specifically
used for anxiety research than others [8].
Test solutions of Gelsemium alcoholic
extracts were made by diluting 1:100 solutions
starting from a raw material containing 30 % or
about 50 mM ethanol [15, 20, 21].
Concentration of gelsemine, a major
component of Gelsemium extract, was
calculated as low as 6.5 9 10-4 M in the fresh
hydroalcoholic raw extract, then diluted 1:100
(6.5 9 10-6 M) in 30 % ethanol (49.93 mmol/L)
and significant evidence reported for tested
solutions containing an estimated
concentration of 6.5 9 10-20 M gelsemine and
4.99 9 10-4 M ethanol [15, 20, 21]. While the
final concentration of ethanol (EtOH) at the so-
called Gelsemium 2CH should be as low as
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5 9 10-6 M and gelsemine calculated as
6.5 9 10-8 M as 2CH means a final dilution
1:10,000, the authors made 1CH (1:100) in 30 %
ethanol (50.5 mM EtOH) and 2CH into water
(0.505 mM EtOH, i.e. 5.05 9 10-4 M EtOH) [15,
20, 21]. Therefore, in Gelsemium 2CH, the ratio
EtOH/gelsemine was about 10,000:1 [15, 20].
Because any further dilution was made with this
approach, this ratio was particularly higher for
EtOH with respect to Gelsemium at 9CH and
even more at 30CH. Comments raised about
this alkaloid/ethanol disproportion, which
suggested a preponderant role from ethanol
respect to Gelsemium components in modifying
mice behaviour in a LDBT and OFT [15], also
highlighted why the evidence was scarcely
reproducible [9, 32]. The authors claimed their
results as promising and explained Gelsemium
ability to reduce anxiety in mice by an
anxiolytic effect attributed to gelsemine and
3a,5a-THP [15]. In their paper, the minimal
effective concentration of gelsemine, estimated
by the iterative dilution process from 6.5 9 10-4
M, was much lower the concentration reported
in recent studies [13, 15].
The same research group recently showed
that diluted hydroalcoholic extracts of
Gelsemium were able to affect gene
transcription in human neuroblastoma models
[19–21]. They reported the same gelsemine
concentration previously shown [20] and a
slight reduction in a microarray gene
expression model on human SH-SY5Y
neuroblastoma cell line with an estimated
concentration of gelsemine as low as
6.5 9 10-9 M, hence within ranges previously
reported for rats [13, 21]. A cognate paper,
published in a niche journal in CAM research,
confirmed the effect of this gelsemine dosage,
but highlighted also a significant effect, though
slight, with doses decisively much lower than
6 nM gelsemine [20]. In both papers, a diluted
hydroalcoholic extract of Gelsemium
downregulated the expression of 49/56 [21] or
45/55 [20] genes in SH-SYS5 neuroblastoma.
Published comments addressed the issue that
the effect observed on gene expression might be
brought up by EtOH carry-over in the test
solution, due to the predominant presence of
EtOH respect to any molecule of the starting
Gelsemium extract [18]. No gene particularly
involved in the neurological mechanism
underlying the molecular action of Gelsemium
alkaloids was up- or downregulated in the
experimental research [18, 20, 21].
FURTHER COMMENTS
AND CONCLUSIVE REMARKS
Comments about the ability of negligible doses
of Gelsemium hydroalcoholic extracts to affect
gene expression were recently reported [18]. In
an attempt to highlight possible conclusive
remarks on the research about Gelsemium, I
will introduce these fundamental concerns.
1. A more general observation of these studies
showed that Gelsemium extract did not
undergo a thorough chemical analysis of
its composition, but many authors
attributed any result to the exclusive effect
of gelsemine [15, 20, 21]. Gelsemium
sempervirens extracts contain alkaloids with
an in toto anxiolytic activity, yet a chemical
definition of these components needs to be
performed [14]. Other oxindole alkaloids
contained in Gelsemium extracts besides
gelsemine exhibit a neurotropic action
[12]. New alkaloids are being discovered
and a complex interaction between
Gelsemium alkaloids and their metabolites
may affect significantly the biological
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response of an organism to plant extracts
[33, 34].
2. Tested solutions contain a sizable molar
fraction of ethanol, with respect to
Gelsemium extract [13, 18]. The analytical
evaluation of gelsemine reported in [21]
should refer to the calculation indicated in
[15], as the authors did not perform and
subsequently describe the concentration of
gelsemine in the alcoholic raw extract used
for the experiment on gene expression [18,
19]. According to this assumption, a
Gelsemium hydroalcoholic extract
containing as low as 6.5 9 10-22 M
gelsemine and 5.0 9 10-4 M ethanol
downregulated the expression of
bombesin-like receptor 3 (BRS3) and
gastrin-releasing peptide receptor (GRPR)
genes in SH-SY5Y cells [20]. Aside from the
consideration about which genes are
possibly expressed by neuroblastoma in a
genomic microarray and how much they
are involved in a behavioural mechanism
[18], Gelsemium hydroalcoholic extracts
appeared to fundamentally affect genes
involved in olfactory and tumor-related
mechanism [20, 35, 36], while changes in
genes related to neurological mechanism
involved in anxiety were not reported [18,
19] This evidence apparently discourages
the promising role of Gelsemium used in
CAM in modulating genes associated with
neuroscience and mood disorders. This
apparently aspecific activity by even
nanomolar concentrations of gelsemine in
Gelsemium might be related also to effects
coming from other Gelsemium components,
their complex interaction or even to
alcoholic solvent, past reports have
outlined a role for bombesin-like peptides
in the neurological control of ethanol
toxicity [37, 38], so EtOH in test solutions
cannot be excluded from any comment
about Gelsemium effect. The authors
incubated SH-SY5Y cells with Gelsemium
hydroalcoholic extracts for 24 h [20, 21];
ethanol itself may exhibit an activity on
neuroblastoma cells at the estimated
concentration of this research for that
time course [39].
3. While the gross bulk of evidence in this
research regards effects with micromolar-
nanomolar concentrations of Gelsemium
alkaloids [12], the lowest doses should
raise criticism for an intrinsic difficulty in
chemical analysis and for ethanol-related
bias. The molar mass of ethanol solvent in
tested solutions approaching a theoretical
concentration of active principles lower
than 1 attomole/L, is at least 16 orders of
magnitude higher. As ethanol is a bioactive
molecule at relatively low doses [18], its
activity on gene expression may be highly
complex and unpredictable, both in treated
and control cells, so hindering a reliable
statistical evaluation of the assay system.
4. Some authors recently reported that
‘‘Perhaps we need to remind that normally,
when one performs a study of dose–response
and the concentration in the highest dose
and the dilution factor are known, there is
no way to determine the concentration of
substances in all successive dilutions…’’ [19].
This suggests that the way Gelsemium in
CAM approaches mood disorders and
anxiety needs this standpoint to be
addressed and further elucidated.
CONCLUSIONS
While increasing evidence reports the
anxiolytic activity of Gelsemium [1–6, 11, 13,
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14], research on its active principles needs
further investigation. A complex panoply of
anti-depressant, sedative, anxiolytic,
neurotropic, nociceptive, and mood modifier
molecules represents the herbal potential of the
Gelsemium plant. In this respect, CAMs using
Gelsemium should reappraise experimental
reports about test setting and molecular
models, in order to reduce misinterpretations,
comments and bias about the pharmacological
interpretation of Gelsemium activity.
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